Natera Secures IVDR Certification for Signatera Across Multiple Cancers
Event summary
- Natera's Signatera received IVDR Class C certification, meeting stringent EU regulatory standards.
- Certification covers adjuvant and surveillance settings across multiple cancer types, including gastrointestinal, genitourinary, lung, breast, and others.
- Follows recent regulatory approvals in Japan (June 2026) and the U.S. (May 2026) for specific cancer indications.
- IVDR certification reduces lead time and regulatory overhead for launching new clinical trials in Europe.
The big picture
Natera's IVDR certification for Signatera underscores the growing importance of rigorous regulatory frameworks in precision oncology. The approval positions Natera to capitalize on Europe's shift toward more stringent diagnostic standards, while recent U.S. and Japan approvals highlight its global expansion strategy. The move comes as minimal residual disease (MRD) testing gains traction as a critical tool for personalized cancer treatment.
What we're watching
- Regulatory Expansion
- How Natera will leverage IVDR certification to accelerate Signatera adoption in Europe ahead of the 2028 IVDD transition deadline.
- Clinical Validation
- Whether the extensive clinical evidence supporting Signatera will translate into broader reimbursement and payer acceptance.
- Competitive Positioning
- The pace at which Natera can differentiate Signatera in a crowded MRD testing market, particularly against Guardant Health and Exact Sciences.
Related topics